Vanda Pharmaceuticals Stock Price, News & Analysis (NASDAQ:VNDA)

$17.30 +0.20 (+1.17 %)
(As of 02/21/2018 08:18 AM ET)
Previous Close$17.10
Today's Range$16.85 - $17.55
52-Week Range$11.90 - $18.99
Volume561,800 shs
Average Volume551,991 shs
Market Capitalization$776.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24

About Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio2.41%
Quick Ratio2.40%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$165.08 million
Price / Sales4.76
Cash FlowN/A
Price / CashN/A
Book Value$2.89 per share
Price / Book5.99

Profitability

Trailing EPS($0.34)
Net Income$-15,560,000.00
Net Margins-9.43%
Return on Equity-11.94%
Return on Assets-7.53%

Miscellaneous

Employees142
Outstanding Shares45,440,000

Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. The biopharmaceutical company had revenue of $44.28 million for the quarter, compared to analysts' expectations of $44 million. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. The company's quarterly revenue was up 15.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.08 earnings per share. View Vanda Pharmaceuticals' Earnings History.

When will Vanda Pharmaceuticals make its next earnings announcement?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Vanda Pharmaceuticals.

Where is Vanda Pharmaceuticals' stock going? Where will Vanda Pharmaceuticals' stock price be in 2018?

6 brokerages have issued twelve-month target prices for Vanda Pharmaceuticals' stock. Their forecasts range from $18.00 to $27.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $22.00 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:

  • H. Thomas Watkins, Independent Chairman of the Board (Age 64)
  • Mihael Hristos Polymeropoulos M.D., President, Chief Executive Officer, Director (Age 57)
  • James Patrick Kelly, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
  • Gian Piero Reverberi, Senior Vice President, Chief Compliance Officer (Age 51)
  • Richard L. Gulino, Senior Vice President, General Counsel, Secretary (Age 54)
  • Gunther Birznieks, Senior Vice President - Business Development (Age 48)
  • Kenneth M. Bate, Independent Director (Age 66)
  • Michael F. Cola, Independent Director (Age 57)
  • Richard W. Dugan, Independent Director (Age 75)
  • Vincent J. Milano, Independent Director (Age 53)

Who owns Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.17%), Armistice Capital LLC (5.96%), Macquarie Group Ltd. (5.05%), Renaissance Technologies LLC (3.19%), Millennium Management LLC (2.51%) and Stonepine Capital Management LLC (1.97%). Company insiders that own Vanda Pharmaceuticals stock include Gunther Birznieks, James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Who sold Vanda Pharmaceuticals stock? Who is selling Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, Deutsche Bank AG, Foundry Partners LLC, Two Sigma Advisers LP, Bogle Investment Management L P DE, Geode Capital Management LLC and HBK Investments L P. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.

Who bought Vanda Pharmaceuticals stock? Who is buying Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Stonepine Capital Management LLC, Macquarie Group Ltd., Renaissance Technologies LLC, Cortina Asset Management LLC, BlackRock Inc., Virtus Fund Advisers LLC and Cadence Capital Management LLC. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy Vanda Pharmaceuticals stock?

Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $17.30.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $776.99 million and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Vanda Pharmaceuticals employs 142 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (VNDA)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  418
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vanda Pharmaceuticals (NASDAQ:VNDA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.00$21.83$22.20$21.75
Price Target Upside: 38.80% upside53.22% upside68.82% upside40.78% upside

Vanda Pharmaceuticals (NASDAQ:VNDA) Consensus Price Target History

Price Target History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018OppenheimerSet Price TargetBuy$27.00HighView Rating Details
2/13/2018Jefferies GroupReiterated RatingBuy$20.00LowView Rating Details
1/19/2018Seaport Global SecuritiesInitiated CoverageBuy -> Buy$20.00MediumView Rating Details
10/19/2017Piper Jaffray CompaniesSet Price TargetBuy$26.00N/AView Rating Details
8/3/2017HC WainwrightSet Price TargetBuy$18.00HighView Rating Details
4/12/2017CIBCReiterated RatingOutperform -> Outperform$21.00LowView Rating Details
11/9/2016AegisInitiated CoverageBuy$24.00N/AView Rating Details
10/10/2016Brean CapitalSet Price TargetBuy$24.00N/AView Rating Details
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 -> $22.00N/AView Rating Details
3/14/2016Canaccord GenuityReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Vanda Pharmaceuticals (NASDAQ:VNDA) Earnings History and Estimates Chart

Earnings by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ VNDA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018($0.17)N/AView Earnings Details
2/14/2018Q4 2017($0.12)($0.04)$44.00 million$44.28 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.10)($0.10)$43.90 million$41.30 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.21)($0.03)$40.31 million$42.06 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.13)($0.17)$38.35 million$37.42 millionViewListenView Earnings Details
2/15/2017Q416($0.06)($0.01)$39.38 million$38.24 millionViewListenView Earnings Details
11/2/2016Q316($0.14)($0.01)$38.05 million$38.48 millionViewListenView Earnings Details
7/27/2016Q216($0.23)($0.11)$36.03 million$36.02 millionViewListenView Earnings Details
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details
2/10/2011($0.02)$0.08ViewN/AView Earnings Details
11/3/2010Q3 2010$0.03$0.11ViewN/AView Earnings Details
8/5/2010Q2 2010$0.10$0.04ViewN/AView Earnings Details
5/4/2010Q1 2010$0.06$0.02ViewN/AView Earnings Details
2/16/2010Q4 2009($0.25)($0.34)ViewN/AView Earnings Details
11/2/2009Q3 2009($0.30)($0.28)ViewN/AView Earnings Details
8/10/2009Q2 2009($0.26)($0.46)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.22)($0.24)ViewN/AView Earnings Details
2/11/2009Q4 2008($0.42)($0.28)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.44)($0.41)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.70)($0.51)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.86)($0.72)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.76)($0.78)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Vanda Pharmaceuticals (NASDAQ:VNDA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.17)($0.12)($0.15)
Q2 20182($0.07)($0.06)($0.07)
Q3 20182($0.57)$0.00($0.29)
Q4 20182($0.06)$0.04($0.01)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 89.13%
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Gunther BirznieksSVPSell8,568$15.26$130,747.68118,366View SEC Filing  
1/2/2018James Patrick KellyCFOSell9,155$15.35$140,529.25144,721View SEC Filing  
1/2/2018Mihael Hristos PolymeropoulosInsiderSell191,760$15.30$2,933,928.001,031,848View SEC Filing  
1/3/2017Richard L GulinoSVPSell10,900$15.51$169,059.0012,500View SEC Filing  
9/23/2016James E FlynnInsiderSell1,120,461$16.56$18,554,834.16View SEC Filing  
9/19/2016James E FlynnInsiderSell547,886$15.66$8,579,894.76View SEC Filing  
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.4460,772View SEC Filing  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88839,178View SEC Filing  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.8040,665View SEC Filing  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52816,781View SEC Filing  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.0015,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vanda Pharmaceuticals (NASDAQ VNDA) News Headlines

Source:
DateHeadline
Research Analysts Issue Forecasts for Vanda Pharmaceuticals Inc.s Q1 2018 Earnings (VNDA)Research Analysts Issue Forecasts for Vanda Pharmaceuticals Inc.'s Q1 2018 Earnings (VNDA)
www.americanbankingnews.com - February 19 at 1:26 AM
Vanda Pharmaceuticals (VNDA) Given a $27.00 Price Target by Oppenheimer AnalystsVanda Pharmaceuticals (VNDA) Given a $27.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - February 17 at 7:40 PM
FY2021 Earnings Forecast for Vanda Pharmaceuticals Inc. (VNDA) Issued By OppenheimerFY2021 Earnings Forecast for Vanda Pharmaceuticals Inc. (VNDA) Issued By Oppenheimer
www.americanbankingnews.com - February 16 at 4:16 PM
Jefferies Group Comments on Vanda Pharmaceuticals Inc.s Q2 2018 Earnings (VNDA)Jefferies Group Comments on Vanda Pharmaceuticals Inc.'s Q2 2018 Earnings (VNDA)
www.americanbankingnews.com - February 16 at 8:34 AM
Vanda Pharmaceuticals (VNDA) CEO Mihael Polymeropoulos on Q4 2017 Results - Earnings Call TranscriptVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 15 at 4:19 PM
FY2018 EPS Estimates for Vanda Pharmaceuticals Inc. Lowered by Analyst (VNDA)FY2018 EPS Estimates for Vanda Pharmaceuticals Inc. Lowered by Analyst (VNDA)
www.americanbankingnews.com - February 15 at 10:56 AM
Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial ResultsVanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results
finance.yahoo.com - February 15 at 6:13 AM
Vanda Pharmaceuticals (VNDA) Announces Quarterly  Earnings ResultsVanda Pharmaceuticals (VNDA) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 14 at 10:44 PM
Jefferies Group Reaffirms "Buy" Rating for Vanda Pharmaceuticals (VNDA)Jefferies Group Reaffirms "Buy" Rating for Vanda Pharmaceuticals (VNDA)
www.americanbankingnews.com - February 13 at 4:16 PM
Vanda Pharmaceuticals (VNDA) Set to Announce Earnings on WednesdayVanda Pharmaceuticals (VNDA) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 7 at 1:56 AM
Vanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from BrokeragesVanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 6 at 1:19 PM
$44.00 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter$44.00 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - February 1 at 2:40 AM
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018
finance.yahoo.com - January 31 at 6:11 AM
FY2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Raised by AnalystFY2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Raised by Analyst
www.americanbankingnews.com - January 24 at 6:26 AM
Vanda Pharmaceuticals (VNDA) Earns Buy Rating from Analysts at Seaport Global SecuritiesVanda Pharmaceuticals (VNDA) Earns Buy Rating from Analysts at Seaport Global Securities
www.americanbankingnews.com - January 20 at 3:28 PM
Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Quarterly Sales of $44.00 MillionVanda Pharmaceuticals Inc. (VNDA) Expected to Post Quarterly Sales of $44.00 Million
www.americanbankingnews.com - January 16 at 10:52 PM
Vanda Pharmaceuticals (VNDA) and Epizyme (EPZM) Head-To-Head AnalysisVanda Pharmaceuticals (VNDA) and Epizyme (EPZM) Head-To-Head Analysis
www.americanbankingnews.com - January 15 at 7:14 PM
 Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) to Announce -$0.12 Earnings Per Share Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) to Announce -$0.12 Earnings Per Share
www.americanbankingnews.com - January 14 at 1:06 AM
Vanda Pharmaceuticals Inc. (VNDA) Receives Average Rating of "Buy" from AnalystsVanda Pharmaceuticals Inc. (VNDA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 12 at 10:00 AM
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 GuidanceVanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance
www.prnewswire.com - January 7 at 11:25 AM
Insider Selling: Vanda Pharmaceuticals Inc. (VNDA) CFO Sells 9,155 Shares of StockInsider Selling: Vanda Pharmaceuticals Inc. (VNDA) CFO Sells 9,155 Shares of Stock
www.americanbankingnews.com - January 4 at 8:26 PM
Vanda Pharmaceuticals Inc. (VNDA) SVP Sells $130,747.68 in StockVanda Pharmaceuticals Inc. (VNDA) SVP Sells $130,747.68 in Stock
www.americanbankingnews.com - January 4 at 8:26 PM
Vanda Pharmaceuticals Inc. (VNDA) Insider Mihael Hristos Polymeropoulos Sells 191,760 SharesVanda Pharmaceuticals Inc. (VNDA) Insider Mihael Hristos Polymeropoulos Sells 191,760 Shares
www.americanbankingnews.com - January 4 at 7:02 PM
Noteworthy Wednesday Option Activity: VMC, SLB, VNDA - NasdaqNoteworthy Wednesday Option Activity: VMC, SLB, VNDA - Nasdaq
www.nasdaq.com - January 4 at 10:29 AM
Zacks: Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.00 MillionZacks: Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.00 Million
www.americanbankingnews.com - December 30 at 11:40 AM
Traders Buy High Volume of Put Options on Vanda Pharmaceuticals (VNDA)Traders Buy High Volume of Put Options on Vanda Pharmaceuticals (VNDA)
www.americanbankingnews.com - December 29 at 1:58 AM
Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.12 Per ShareVanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - December 28 at 8:30 AM
-$0.12 Earnings Per Share Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter-$0.12 Earnings Per Share Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - December 28 at 8:30 AM
ETFs with exposure to Vanda Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Vanda Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 8:23 PM
Jefferies Group Comments on Vanda Pharmaceuticals Inc.s FY2019 Earnings (VNDA)Jefferies Group Comments on Vanda Pharmaceuticals Inc.'s FY2019 Earnings (VNDA)
www.americanbankingnews.com - December 25 at 2:40 PM
Vanda Pharmaceuticals (VNDA) Upgraded to "Hold" by BidaskClubVanda Pharmaceuticals (VNDA) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - December 23 at 12:16 AM
Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
finance.yahoo.com - December 22 at 10:45 AM
Vanda Pharmaceuticals (VNDA) Lifted to "Hold" at ValuEngineVanda Pharmaceuticals (VNDA) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - December 20 at 10:10 PM
Vanda Pharmaceuticals, Inc. is trading above its 50 day moving average : VNDA-US : December 20, 2017Vanda Pharmaceuticals, Inc. is trading above its 50 day moving average : VNDA-US : December 20, 2017
finance.yahoo.com - December 20 at 10:36 AM
Vanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from AnalystsVanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 18 at 9:56 AM
Reviewing Vanda Pharmaceuticals (VNDA) & Achaogen (AKAO)Reviewing Vanda Pharmaceuticals (VNDA) & Achaogen (AKAO)
www.americanbankingnews.com - December 17 at 7:28 PM
Vanda Pharmaceuticals Inc. (VNDA) Expected to Announce Quarterly Sales of $44.00 MillionVanda Pharmaceuticals Inc. (VNDA) Expected to Announce Quarterly Sales of $44.00 Million
www.americanbankingnews.com - December 12 at 2:50 AM
Vanda Pharmaceuticals Inc. (VNDA) Given Average Recommendation of "Buy" by BrokeragesVanda Pharmaceuticals Inc. (VNDA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 23 at 1:54 PM
Zacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (VNDA) to Announce -$0.12 Earnings Per ShareZacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (VNDA) to Announce -$0.12 Earnings Per Share
www.americanbankingnews.com - November 23 at 1:28 AM
Zacks: Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.00 MillionZacks: Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.00 Million
www.americanbankingnews.com - November 19 at 8:42 AM
Vanda Pharmaceuticals Inc. (VNDA) to Post Q3 2018 Earnings of $0.00 Per Share, Oppenheimer Holdings ForecastsVanda Pharmaceuticals Inc. (VNDA) to Post Q3 2018 Earnings of $0.00 Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - November 14 at 10:48 AM
Oppenheimer Holdings, Inc. Reaffirms "Buy" Rating for Vanda Pharmaceuticals Inc. (VNDA)Oppenheimer Holdings, Inc. Reaffirms "Buy" Rating for Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - November 13 at 2:27 PM
FDA Nod For BMYs Sprycel, ARNA To Report Data In Q1, MYL Delists From TASEFDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE
www.rttnews.com - November 13 at 11:12 AM
Vanda Pharmaceuticals Announces Participation at November 2017 Investor ConferencesVanda Pharmaceuticals Announces Participation at November 2017 Investor Conferences
finance.yahoo.com - November 13 at 11:12 AM
Reviewing Vanda Pharmaceuticals (VNDA) & Its PeersReviewing Vanda Pharmaceuticals (VNDA) & Its Peers
www.americanbankingnews.com - November 13 at 3:34 AM
FY2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Boosted by AnalystFY2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Boosted by Analyst
www.americanbankingnews.com - November 13 at 1:48 AM
Jefferies Group Comments on Vanda Pharmaceuticals Inc.s FY2020 Earnings (VNDA)Jefferies Group Comments on Vanda Pharmaceuticals Inc.'s FY2020 Earnings (VNDA)
www.americanbankingnews.com - November 10 at 7:46 PM
Traders Purchase Large Volume of Put Options on Vanda Pharmaceuticals (VNDA)Traders Purchase Large Volume of Put Options on Vanda Pharmaceuticals (VNDA)
www.americanbankingnews.com - November 10 at 1:08 AM
Edited Transcript of VNDA earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of VNDA earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 9:35 AM
Vanda Pharmaceuticals (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 4:19 AM

SEC Filings

Vanda Pharmaceuticals (NASDAQ:VNDA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vanda Pharmaceuticals (NASDAQ:VNDA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vanda Pharmaceuticals (NASDAQ VNDA) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.